EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Validation of new equipment for SARS-CoV-2 diagnosis in Ecuador: Detection of the virus and antibodies generated by disease and vaccines with one POC device

Stephany D Villota iD, Eliana Veloz-Villavicencio iD, Santiago Garcia-Iturralde, Johanna Valentina Arévalo, Suying Lu, Katariina Jaenes, Yuxiu Guo, Seray Cicek, Karen Colwill iD, Anne-Claude Gingras, Rod Bremner, Patricio Ponce und 2 weitere

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0321794 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift PLOS ONE, 2025. Verfasst von Stephany D Villota und 13 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigación en Enfermedades Infecciosas y Vectoriales (CIREV), Instituto Nacional de Investigación en Salud Pública (INSPI), Quito, Ecuad…. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antibodies, Viral. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: International Development Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic underscored the critical need to enhance screening capabilities and streamline diagnosis. Point-of-care (POC) tests offer a promising solution by decentralizing testing. We aimed to validate the PLUM device (LSK Technologies Inc.), a portable optical reader, to detect SARS-CoV-2 RNA using direct RT-LAMP targeting the ORF1a and E1 genes and patient antibodies by ELISA. The direct RT-LAMP assays employ nasopharyngeal swabs and bypass RNA extraction protocols through a brief chemical and physical lysis step. Test sensitivity and specificity were assessed against gold-standard detection methods in laboratory and field conditions. For samples with Ct values below 25, direct RT-LAMP showed 83% sensitivity and 90% specificity under laboratory conditions and 91% sensitivity and 92% specificity under field conditions. The nucleocapsid antigen antibody assay had 99% positive percent agreement (PPA) and 97% negative percent agreement (NPA), outperforming spike-RBD antigen (98% PPA, 92% NPA) and seroprevalence (98% PPA, 88% NPA) under laboratory conditions. Under field conditions, similar results were found for antibody detection for the nucleocapsid antigen (93% PPA; 100% NPA), spike-RBD (100% PPA; 94% NPA), and seroprevalence (90% PPA; 94% NPA). This study validated the PLUM device as a dual POC tool for direct RT-LAMP-based SARS-CoV-2 and ELISA-based COVID-19 antibody detection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2Antibodies, ViralHumansEcuadorNucleic Acid Amplification TechniquesSensitivity and SpecificityRNA, ViralEnzyme-Linked Immunosorbent AssayCOVID-19 VaccinesPoint-of-Care SystemsCOVID-19 TestingMolecular Diagnostic Techniques

Substanzen

Antibodies, ViralRNA, ViralCOVID-19 Vaccines

Autor:innen und Institutionen

  • Centro de Investigación en Enfermedades Infecciosas y Vectoriales (CIREV), Instituto Nacional de Investigación en Salud Pública (INSPI), Quito, Ecuador.
  • Facultad de Ciencias Médicas y Bienestar. Universidad Iberoamericana del Ecuador - UNIB.E, Quito, Ecuador.
  • Departamento de Ciencias de la Vida y la Agricultura, Universidad de las Fuerzas Armadas ESPE, Sangolquí, Ecuador.
  • Escuela de Enfermería, Facultad de Ciencias de la Salud, Universidad de las Américas, Quito, Ecuador.
  • Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, Ontario, Canada.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Stephany D Villota, Eliana Veloz-Villavicencio, Karen Colwill, Varsovia Enid Cevallos

Förderung

  • International Development Research Centre

Zitieren

APA

Villota, S. D., Veloz-Villavicencio, E., Garcia-Iturralde, S., Arévalo, J. V., Lu, S., Jaenes, K., Guo, Y., Cicek, S., Colwill, K., Gingras, A. C., Bremner, R., Ponce, P., Pardee, K., & Cevallos, V. E. (2025). Validation of new equipment for SARS-CoV-2 diagnosis in Ecuador: Detection of the virus and antibodies generated by disease and vaccines with one POC device. PLOS ONE. https://doi.org/10.1371/journal.pone.0321794

Vancouver

Villota SD, Veloz-Villavicencio E, Garcia-Iturralde S, Arévalo JV, Lu S, Jaenes K, et al. Validation of new equipment for SARS-CoV-2 diagnosis in Ecuador: Detection of the virus and antibodies generated by disease and vaccines with one POC device. PLOS ONE. 2025. doi:10.1371/journal.pone.0321794

BibTeX
@article{Villota2025,
  author = {Villota, Stephany D and Veloz-Villavicencio, Eliana and Garcia-Iturralde, Santiago and Arévalo, Johanna Valentina and Lu, Suying and Jaenes, Katariina and Guo, Yuxiu and Cicek, Seray and Colwill, Karen and Gingras, Anne-Claude and Bremner, Rod and Ponce, Patricio and Pardee, Keith and Cevallos, Varsovia Enid},
  title = {Validation of new equipment for SARS-CoV-2 diagnosis in Ecuador: Detection of the virus and antibodies generated by disease and vaccines with one POC device},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0321794}
}
Kostenlos starten →